Cathie Wood Sells Meta and Illumina, Loads Up on Early-Stage Genomics Stocks

TLDR

• ARK Invest purchased $15.88 million worth of GeneDx Holdings stock after shares dropped 11.9% on January 12
• Cathie Wood sold $13.29 million in Illumina shares and $12.7 million in Meta Platforms stock last week
• ARK bought shares in Intellia Therapeutics, 10X Genomics, and Personalis as part of biotech portfolio expansion
• Wood trimmed positions in Natera, Teradyne, Beam Therapeutics, Roku, and Palantir Technologies
• ARK added advanced air mobility stocks Joby Aviation and Archer Aviation through space exploration ETF

Cathie Wood’s ARK Invest executed major portfolio shifts on January 12, with regulatory filings revealing the firm bought $15.88 million in GeneDx Holdings stock. The purchase came after GeneDx shares fell 11.9% when the company issued guidance that failed to meet investor expectations despite strong preliminary fiscal 2025 results.

GeneDx Holdings Corp., WGS

ARK acquired 133,191 shares of GeneDx through the ARK Innovation ETF and ARK Genomic Revolution ETF. GeneDx operates as a global leader in rare disease diagnosis and maintains the largest genomic dataset in that sector.

Wood also purchased 99,292 shares of Intellia Therapeutics for approximately $1.13 million. The clinical-stage biotech company saw shares jump 10.2% on the same trading day. ARK added 49,963 shares of 10X Genomics after the stock declined 3.2% and bought 17,748 shares of Personalis.

ARK Exits Illumina and Meta Positions

Wood sold 91,312 shares of Illumina for $13.29 million on January 12. The sale indicates ARK is shifting away from established genomics companies toward earlier-stage competitors. Illumina stock has climbed nearly 48% over the previous six months.

Last week, ARK sold roughly $12.7 million in Meta Platforms shares across multiple ETFs including ARK Innovation ETF, ARKW, and ARKF. The sales represent a continued move away from large-cap tech and social media companies.

ARK reduced several other positions on January 12. The firm sold $2.61 million in Natera stock, $5.15 million in Teradyne shares, and $1.11 million in Beam Therapeutics. Wood also made a smaller sale in Ionis Pharmaceuticals stock.

New Positions in Aviation and Automation

While trimming tech holdings, ARK added positions in emerging sectors. The ARK Space Exploration & Innovation ETF purchased shares of Joby Aviation and Archer Aviation. Both companies develop electric vertical takeoff and landing aircraft for urban transportation.

ARK also bought Deere & Company stock, targeting automation opportunities in construction and agriculture. Last week’s portfolio changes included trimming Roku and Palantir Technologies positions.

The trading activity shows Wood moving capital from mature market leaders toward disruptive innovation companies. ARK’s biotech purchases focus on genomics and gene therapy firms at earlier development stages. The Illumina and Meta sales represent exits from established companies that have grown in the current market cycle.

Wood’s trades across multiple ARK ETFs total more than $50 million in combined buy and sell transactions. The portfolio changes emphasize ARK’s investment thesis around disruptive technologies in healthcare, autonomous transport, and advanced manufacturing sectors. ARK’s strategy prioritizes long-term growth opportunities in companies developing breakthrough technologies over established tech giants.

The post Cathie Wood Sells Meta and Illumina, Loads Up on Early-Stage Genomics Stocks appeared first on Blockonomi.